

Please type a plus sign (+) inside this box →

+

RECEIVED

JUN 10 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/935,061
Sheet 1 of 4			Filing Date	August 21, 2001
			First Named Inventor	Kobilka, et al.
			Group Art Unit	4645-1646
			Examiner Name	Unassigned Ruixiang Li
			Attorney Docket Number	STAN-213

RECEIVED
JUN 10 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ²
RLi	\	ALTENBACH, et al. "Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: A site-directed spin-labeling study", Biochemistry Vol. 35(38): 12470-12478 (1996).	
	\	ARINS, et al. "A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin", J. Biol. Chem. Vol. 269: 23879-23881 (1994).	
	\	DUNHAM, et al. "Conformational changes in rhodopsin", J. Biol. Chem. Vol. 274: 1683-1690 (1999).	
	\	FARAHBAKHS, et al. "Photoactivated conformational changes in rhodopsin: A time-resolved spin label study", Science Vol. 262: 1416-1419 (1993).	
	\	FARRENS, et al. "Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin", Science Vol. 274(5288): 768-770 (1996).	
	\	FRAUENFELDER, et al. "The energy landscapes and motions of proteins", Science Vol. 254: 1598-1603 (1991).	
	\	FREIRE. "Can allosteric regulation be predicted from structure?", PNAS Vol. 97(22): 11680-11682 (2000).	
\	\	GETHER, et al. "Fluorescent labeling of purified β_2 adrenergic receptor", J. Biol. Chem. Vol. 270(47): 28268-28275 (1995).	

Examiner Signature	Ruixiang Li	Date Considered	8/21/03
--------------------	-------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

JUN 10 2002



TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/935,061
Sheet	2	of	4
		Filing Date	August 21, 2001
		First Named Inventor	Kobilka, et al.
		Group Art Unit	1645 1646
		Examiner Name	Unassigned Ruixiang
		Attorney Docket Number	STAN-213

RECEIVED

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ²
RLi	\	GETHER, et al. "Agonists induce conformational changes in transmembrane domains III and VI of the β_2 receptor", EMBO J. Vol. 16(22): 6737-6747 (1997).	
	\	GHANOUNI, et al. "The effect of pH on β_2 adrenoceptor function", J. Biol. Chem. Vol. 275: 3121-3127 (2000).	
	\	GILMAN. "G Proteins: transducers of receptor-generated signals", Annu. Rev. Biochem. Vol. 56: 615-649 (1987).	
	\	GINTY. "Calcium regulation of gene expression: Isn't that spatial?", Neuron Vol. 18: 183-186 (1997).	
	\	GUDERMANN, et al. "Functional and structural complexity of signal transduction via G Protein-coupled receptors", Annu. Rev. Neurosci. Vol. 20: 399-427 (1997).	
	\	HAMM. "The many faces of G-Protein signaling", The Journal of Biological Chemistry Vol. 273: 669-672 (1998).	
	\	HOSHI, et al. "Shaker Potassium channel gating I: Transitions near the open state", J. Gen. Physiol. Vol. 103(2): 249-278 (1994).	
	\	Ji, et al. "G-Protein coupled receptors", The Journal of Biological Chemistry Vol. 273: 17229-17302 (1998).	
	\	KENAKIN. "The classification of seven transmembrane receptors in recombinant expression systems", Pharmacological Review Vol. 48: 413-463 (1996).	
	\	KENAKIN. "Agonist-specific receptor conformations", Trends Pharmacol. Sci. Vol. 18(11): 416-417 (1997).	
	\	KOBILKA. "The role of cytosolic and membrane factors in processing of the human β_2 adrenergic receptor following translocation and glycosylation in a cell-free system", J. Biol. Chem. Vol. 265(13): 7610-7618 (1990).	
	\	KOBILKA. "Amino and carboxyl terminal modifications to facilitate the production and purification of a G-Protein-coupled receptor", Anal. Biochem. Vol. 231(1): 269-271 (1995).	
	\	KRUMINS, et al. "The stability of the agonist β_2 -Adrenergic receptor- G_s complex: Evidence for agonist-specific states", Mol. Pharmacol. Vol. 52(1): 144-154 (1997).	
	\	LEE, et al. "Restricting the mobility of $G_{s\alpha}$: Impact on receptor and effector coupling", Biochemistry Vol. 38: 13801-13809 (1999).	
RLi	\	LEFF. "The two-state model of receptor activation", TIPS Vol. 16: 89-97 (1995).	


Examiner Signature	Ruixiang L	Date Considered	8/21/03
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



RECEIVED

JUN 10 2002

PTO/SB 087 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	09/935.061 August 21, 2001 Kobilka, et al. 1645-1646 Unassigned Ruixiang Li STAN-213
Sheet	3	of	4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
RLi	\	LEFKOWITZ, et al. "Adenylate cyclase-coupled beta-adrenergic receptors: Structure and mechanisms of activation and desensitization", Ann. Rev. Biochem. Vol. 52: 159-186 (1983).	
	\	LEFKOWITZ, et al. "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins", TIPS Vol. 14: 304-307 (1993).	
	\	MATKO, et al. "Luminescence quenching by nitroxide spin labels in aqueous solution: Studies on the mechanism of quenching", Biochemistry Vol. 31: 703-711 (1992).	
	\	PALCZEWSKI, et al. "Crystal structure of rhodopsin: A G-Protein-coupled receptor", Science Vol. 289: 739-745 (2000).	
	\	PAROLA, et al. "Site-specific fluorescence labeling of the β_2 adrenergic receptor amino terminus", Anal. Biochem. Vol. 254: 88-95 (1997).	
	\	PEREZ, et al. "Constitutive activation of a single effector pathway: Evidence for multiple activation states of a G Protein-coupled receptor", Mol. Pharmacol. Vol. 49(1): 112-122 (1996).	
	\	SAKMAR. "Rhodopsin: A prototypical G-Protein-coupled receptor", Progress in Nucleic Acid Research and Molecular Biology Vol. 59: 1-34 (1998).	
	\	SALAMON, et al. "Plasmon resonance studies of agonist/antagonist binding to the human δ -opioid receptor: New structural insights into receptor-ligand interactions", Biophysical Journal Vol. 79: 2463-2474 (2000).	
	\	SAMAMA, et al. "A mutation-induced activation state of the β_2 -adrenergic receptor", Journal of Biological Chemistry Vol. 268(7): 4625-4636 (1993).	
	\	SCHMIDT. "One-step affinity purification of bacterially produced proteins by means of the "Strep tag" and immobilized recombinant core streptavidin", Journal of Chromatography Vol. 676: 337-345 (1994).	
	\	SELLEY, et al. " μ -Opioid receptor-stimulated guanosine-5'-O-(γ -thio)-triphosphate binding in rat thalamus and cultures cell lines: signal transduction mechanisms underlying agonist efficacy", Mol. Pharmacol. Vol. 51(1): 87-96 (1997).	
RLi	\	SHEIKH, et al. "Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F", Nature Vol. 383: 347-350 (1996).	

Examiner Signature	Ruixiang Li	Date Considered	8/21/03
--------------------	-------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box →



PTO/USPO/08A (08-00)

Approved for use through 10/31/2002. AIA 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/935,061	
			Filing Date	August 21, 2001	
			First Named Inventor	Kobilka, et al.	
			Group Art Unit	1645 1646	
			Examiner Name	Unassigned Ruixiang	
Sheet	4	of	4	Attorney Docket Number	STAN-213

RECEIVED
 JUN 10 2002
 TELETYPE CENTER 1600/2900

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ²
RLi	1	STAMMERS, et al. "Rapid purification and characterization of HIV-1 reverse transcriptase and RnaseH engineered to incorporated a C-terminal tripeptide α -tubulin epitope", FEBS Vol. 283: 298-302 (1991).	
	1	STRADER, et al. "Structure and function of G Protein-coupled receptors", Annu. Rev. Biochem. Vol. 63: 101-132 (1994).	
	1	STRANGE. "G-Protein coupled receptors", Biochem. Pharmacol. Vol. 58(7): 1081-1088 (1999).	
	1	SUBRAMANIAM, et al. "Molecular mechanism of vectorial proton translocation by bacteriorhodopsin", Nature Vol. 406: 653-657 (2000).	
	1	TOTA, et al. "Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system", Mol. Pharmacol. Vol. 37(6), 996-1004 (1990).	
RLi	1	TUCEK. "Is the R and R* dichotomy real?", TIPS. Vol. 18(11): 414-416 (1997).	

Examiner Signature	Ruixiang L.	Date Considered	8/21/03
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Applicant Number	09/935,061
		Filing Date	August 21, 2001
		First Named Inventor	KOBILKA, BRIAN K.
		Group Art Unit	4645-1646
		Examiner Name	To Be Assigned Ruixiang Li
Sheet 1 of 1	Attorney Docket Number	STAN-213	

RECEIVED

AUG 08 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		GHANOUNI, et al. "Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor", <i>Proc. Natl. Acad. Sci. USA</i> , (2001) Vol. 98(11): 5997-6002.	
		GHANOUNI, et al. "Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor", <i>J. Biol. Chem.</i> , (2001) Vol. 276(27): 24433-24436.	
		JENSEN, et al. "Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling", <i>J. Biol. Chem.</i> , (2001) Vol. 276(12): 9279-9290.	
RLi		YANG, et al. "Structure and function in rhodopsin. Cysteines 65 and 316 are in proximity in a rhodopsin mutant as indicated by disulfide formation and interactions between attached spin labels", <i>Biochem.</i> , (1996) Vol. 35: 14040-14046.	

Examiner Signature	Ruixiang Li	Date Considered	8/21/03
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.